News Release

Targeting cancer’s antioxidant defenses could help overcome treatment resistance

Peer-Reviewed Publication

Compuscript Ltd

FIG 1

image: 

Image Caption: Regulation of Nrf2 activity.

view more 

Credit: GAD

 

A new review in Genes & Diseases highlights a potential vulnerability in colorectal cancer: the antioxidant defenses that help tumor cells survive treatment. The article examines how adjusting the activity of Nrf2, a regulator of these defenses, could help activate cell death pathways and address drug resistance.

 

Prepared by a team at China Medical University and affiliated hospitals, the review explores a balancing act. Nrf2 protects healthy intestinal cells from oxidative damage, yet persistent activation in cancer cells can strengthen their defenses and reduce sensitivity to chemotherapy. This dual role makes the pathway a promising but challenging therapeutic target.

 

At the center of this balance are reactive oxygen species, reactive molecules generated during cellular activity. Cancer cells operate under heightened oxidative stress and depend on protective systems to keep these molecules within tolerable limits. Disrupting that balance may push tumor cells toward death, although healthy tissues also require protection.

 

The review focuses on three interconnected processes: apoptosis, the controlled dismantling of cells; ferroptosis, an iron-dependent form of cell death driven by damage to membrane fats; and autophagy, the recycling machinery that can support survival or contribute to cell death depending on circumstances.

 

Nrf2 influences these processes by regulating antioxidant production, iron handling and cellular stress responses. In particular, it can suppress ferroptosis by reinforcing defenses against lipid damage. Inhibiting those defenses could make some colorectal cancer cells more vulnerable to treatments designed to trigger ferroptosis or increase oxidative stress.

 

However, the article emphasizes that switching Nrf2 off is not a universal solution. Under certain conditions, activating the pathway can also contribute to anticancer effects or protect normal intestinal tissue during treatment. Effective strategies therefore depend on the biological context, the medicine involved and the cells being targeted.

 

Potential approaches include combining Nrf2 modulators with chemotherapy, radiotherapy or agents that promote cell death pathways. Tumor-targeted delivery systems, including nanoparticles, may help concentrate treatment within cancer tissue while limiting effects elsewhere.

 

The review also highlights the importance of biomarkers, including Nrf2 pathway activity and related genetic features, to identify patients most likely to benefit. Interactions with immune cells and other supporting cells surrounding tumors add another layer of complexity.

# # # # # #

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus CiteScore: 10.4 |Impact Factor:14.6

# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).

Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).

Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)

# # # # # #

Reference

Yichen Yu, Bin Ma, Yue Liu, Ziyi Wang, Jian Chen, Xiaoxi Li, Shulan Sun, Simeng Bao, Rewiring redox defense: Nrf2-driven antioxidant signaling as a gateway to programmed cell death activation in colorectal cancer, Genes & Diseases, Volume 14, Issue 1, 2027, 102228, https://doi.org/10.1016/j.gendis.2026.102228

Funding

Liaoning Provincial Department of Science and Technology Doctoral Launch (China) 2024-BS-317

National Natural Science Foundation of China (No. 82204090

Outstanding Youth Foundation of Liaoning, China 2022-YQ-08


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.